1 Drug Safety Oversight Board Update DIA Annual Meeting Philadelphia, PA June 21 st, 2006 Susan K. Cummins, MD, MPH Executive Director Drug Safety Oversight.

Slides:



Advertisements
Similar presentations
10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.
Advertisements

5th Annual PBM Pharmacy Informatics Conference
Federal Audit Executive Council (FAEC) June 2012 Bi-Monthly Meeting Heather I. Keister Doris G. Yanger June 14, 2012 Green Book Update.
Quality Improvement/ Quality Assurance Amelia Broussard, PhD, RN, MPH Christopher Gibbs, JD, MPH.
FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
FDA and Communication about Regulated Products Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee August.
Lessons Learned in Initiating and Conducting Risk Assessments within a Risk Analysis Framework: A FDA/CFSAN Approach Robert Buchanan DHHS Food and Drug.
Special Topics in IND Regulation
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Rx/OTC Medications Los Angeles Metropolitan Transportation Authority Carol Holben, LCSW, CEAP, SAP Medical Standards & Compliance Administrator Human Resources.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
April 8, 2005FDLI Annual Conference 1 Labeling Prescription Drugs for Physicians and Consumers (FDA Perspective) Paul J. Seligman, MD, MPH Director, Office.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
CASTRO VALLEY ADULT AND CAREER EDUCATION CMA PROGRAM FOOD AND DRUG ADMINISTRATION.
THE ROLE OF DSMB’s in CLINICAL RESEARCH Data and Safety Monitoring Monitoring.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.
FDA Risk Management Workshop: Concept Paper: Risk Management Programs April 10, 2003 Gary C. Stein, Ph.D. Director of Federal Regulatory Affairs American.
New Drug Safety Initiatives & the Drug Safety Oversight Board Drug Safety and Risk Management Advisory Committee, Gaithersburg, MD February 10 th, 2006.
1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.
1 Best Practices in Stakeholder Involvement Paul J. Seligman, M.D., M.P.H. Associate Director, Safety Policy & Communication Center for Drug Evaluation.
Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.
1 PhRMA Guiding Principles - DTC About Prescription Medicines.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.
1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.
1 Assessing Cancer Risk & Assuring Safe Use of Topical Immunosuppressants: Recent History Susan K. Cummins, MD, MPH Medical Team Leader OCTAP and OPT.
Strategies to Consider to Improve ACCV Effectiveness Presentation to ACCV Vito Caserta M.D., M.P.H. Vincent Matanoski, J.D. December 5,
An Update of COSO’s Internal Control–Integrated Framework
FDA Regulatory and Compliance Symposium
Expanding the Capacity for Comparative Effectiveness Research
Investigational Devices and Humanitarian Use Devices June 2007.
FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.
Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.
Risk Management of Modified- Release Opiate Analgesics: Palladone Sharon Hertz, M.D. Medical Team Leader, Analgesics Division of Anesthetic, Critical Care,
Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 19, 2002.
Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 20, 2002.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.
Risk Management, Risk Communication, and Drug Safety: The U.S. Experience Geoffrey Levitt Chief Regulatory Counsel Wyeth August 23, 2007.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
1 Risk Management Considerations for Romiplostim Suzanne Berkman, PharmD Senior Risk Management Analyst Division of Risk Management Office of Surveillance.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
1 FDA’s Communication of Drug Safety Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research December 7-8, 2005 Welcome – Opening Remarks.
1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.
FDA’s Patient Advocacy Programs: Patient Representative Program & Patient Network Andrea Furia-Helms, MPH James Valentine, MHS Office of Special Health.
Abuse-Deterrent Opioids: FDA’s Role and Emerging Challenges Jeanne Ireland Principal, Ireland Strategies, LLC 2015 CWAG Annual Meeting.
Care and Social Services Inspectorate Wales (CSSIW) Supporting the improvement of social care, child care and social services in Wales.
Research ethics.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.
FDA’s IDE Decisions and Communications
NHLBI Perspective Yves Rosenberg, M.D, M.P.H.
Black Box Warning What You Need To Know.
An Update of COSO’s Internal Control–Integrated Framework
Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.
Presentation transcript:

1 Drug Safety Oversight Board Update DIA Annual Meeting Philadelphia, PA June 21 st, 2006 Susan K. Cummins, MD, MPH Executive Director Drug Safety Oversight Board Center for Drug Evaluation and Research Food and Drug Administration

2 Today’s Talk  Review the first year’s activities for the Drug Safety Oversight Board  Provide update on other DSB Activities Draft Drug Watch Guidance Posting of information sheets about emerging important drug safety concerns

3 Definition: Important Drug Safety Issue A Drug Safety issue with the potential to:  Significantly alter the risk-benefit analysis of a drug  Affect physician’s decision to prescribe  Affect patient’s decision to use  Includes and is broader than regulatory definition of “serious and/or life-threatening” adverse event

4 Drug Safety Oversight Board

5 Definition: Oversight Oversight 1 (n): 1. Watchful care or management; supervision. 2. An unintentional omission or mistake. 1 The American Heritage® Dictionary of the English Language, Fourth Edition, 2000 by Houghton Mifflin Company

6 Drug Safety Oversight Board Charge  Provide independent oversight and advice to Center Director on: Management of Important Drug Safety Issues Adjudication of organizational disputes Policies about management of drug safety issues Risk communication about important emerging drug safety concerns Development of HCP & patient information sheets

7 Drug Safety Oversight Board Operational Principles  Fosters effective CDER management of important emerging drug safety concerns  DOES NOT replace Public Advisory Committees  DOES NOT replace current internal responsibility for Regulatory Decision-making

8 Drug Safety Oversight Board: the First Year  Held nine meetings June 17 th 2005 to June 15 th 2006 Public Summaries are at: OBmeetings/default.htm OBmeetings/default.htm

9 Drug Safety Oversight Board: the First Year  Focus of meetings Didactic sessions about CDER processes Defining role within CDER Advising on when and what to communicate about emerging risk Consider how to track emerging important drug safety issues Pre-decisional discussions about many drugs

10 When does FDA communicate about emerging risk? Factors that favor early communication:  If a new risk is a “important drug safety concern” Affects prescribing or monitoring  When there are measures to be taken to prevent harm  If unapproved (off-label) use poses a significant and/or yet undescribed risk  If a specific and/or vulnerable subpopulation may be affected (children or the elderly)

11 DSB does Not Replace AC Meetings or Reduce Public Input  DSB Meetings : Many products discussed Process-oriented Surfaces & addresses internal conflicts Discusses confidential commercial information  AC Meetings : Reviews single drug or drug class Regulatory action oriented Venue for obtaining public input FDA information provided to public

12 Drug Safety Oversight Board Staff Activities

13 Proposed Drug Watch Draft Guidance  Many comments  Support for early communication; unfavorable comments about Watch concept  Comments have been collated, synthesized & evaluated by team  New draft under development

14 Risk Communication Venues for Patients and the General Public  Plain Language health communication  Public Health Advisory Summarizes the specific public health concern with actions to take  Patient Information Sheet “FDA Alert” summarizing safety concern Highlights about product from the approved label

15 Risk Communication Venue for Health Care Professionals  Health Care Professional Information Sheet “FDA Alert” summarizing the safety concern  Recommendations and Considerations— implications for practice  Information & data that are the basis for concern  Studies being done to better understand the concern

16 Drug Safety Alert Challenges  Striking the right balance—don’t want to Over warn OR Under warn  Communicating complex information simply  Determining when to inform the public when the nature of the data is evolving and early  Anticipating & managing unintended consequences  Balancing the communication of emerging risk with communication of benefit

17

18 Drug Safety HC Professional and Patient Information Sheets  At least 49 drugs with safety postings through May Product class issues 3 Market suspensions  Palladone ( hydromorphone hydrochloride ext release)  Tysabri (natalizumab) (Return to Market 06/05/06)  Neutrospec [Technetium (99m Tc) fanolesomab] 3 Product withdrawals  Bextra (valdecoxib)  Cylert (pemoline)  Tequin (gatifloxin) 40 with added warnings to product label

19 Drug Class Risks Described in HC Professional & Patient Information Sheets  Antidepressants—suicidality in adults & children  Atypical antipsychotics—increased risk of death in dementia (unapproved use)  Non-steroidal anti-inflammatory drugs—increased cardiovascular risk  Erectile dysfunction drugs—non-arteritic anterior ischemic optic neuropathy  Topical Immunosuppressant calcineurin inhibitors— potential cancer risk  Long-acting beta agonists—increased risk of severe asthma episodes that may lead to death

20 Drug Safety HC Professional & Patient Information Sheets: Examples  Accutane (isotretinoin)—new restricted access program to prevent pregnancy in treated women  Paxil (paroxetine)—Pregnancy Category changed--C to D  Strattera (atomoxetine)—increased pediatric suicidality risk  Palladone (hydromorphone)— Withdrawn due to dose dumping with concomitant alcohol exposure  Campath (alemtuzumab)—idiopathic thrombocytopenic purpura in patients with multiple sclerosis (unlabeled use)  Neutrospec (99mTechnetium fanolesomab)—serious and life threatening cardiopulmonary events shortly after administration

21 Summary  Drug Safety Oversight Board and its risk communication efforts are a major component of CDER’s effort to strengthen drug safety efforts Sharing emerging important issues early Improving management through internal oversight

22